title: Community Perspectives Associated With the African PsA-TT (MenAfriVac) Vaccine Trials.
abstract: BACKGROUND
  The Meningitis Vaccine Project (MVP) was established to address epidemic meningitis as a public health problem in sub-Saharan Africa and, to that end, worked to develop a group A meningococcal conjugate vaccine, PsA-TT.
  
  
  METHODS
  Experiences in 4 clinical trial sites are described. Culturally sensitive collaborative strategies were adopted to manage acceptable communication methods, peculiarities with the consent process, participant medical issues, community care, and death.
  
  
  RESULTS
  The clinical trials were completed successfully through community acceptance and active community collaboration. The trials also strengthened the capacities in the participating communities, and actively worked to resolve community problems.
  
  
  CONCLUSIONS
  The understanding and integration of sociocultural realities of communities were major assets in the conduct and acceptance of these trials. MVP succeeded in these sites and provided a sound example for future clinical studies in Africa.
  
  
  BACKGROUND
  ISRTCN78147026 (PsA-TT 002); ISRCTN87739946 (PsA-TT 003); ISRCTN82484612 (PsA-TT 004); PACTR ATMR2010030001913177 (PsA-TT 006); and PACTR201110000328305 (PsA-TT 007).
authors.affiliation: Vaccines and Immunity Theme, Medical Research Council Unit, Basse, The Gambia.
authors.forename: Olubukola T
authors.initials: OT
authors.lastname: Idoko
authors.affiliation: Institut de Recherche pour le Développement, Niakhar, Senegal.
authors.forename: Aldiouma
authors.initials: A
authors.lastname: Diallo
authors.affiliation: Centre pour le Développement des Vaccins, Ministère de la Santé, Bamako, Mali.
authors.forename: Samba O
authors.initials: SO
authors.lastname: Sow
authors.affiliation: Navrongo Health Research Centre, Ghana Health Service, Navrongo, Ghana.
authors.forename: Abraham
authors.initials: A
authors.lastname: Hodgson
authors.affiliation: Vaccines and Immunity Theme, Medical Research Council Unit, Basse, The Gambia.
authors.forename: Adebayo
authors.initials: A
authors.lastname: Akinsola
authors.affiliation: Institut de Recherche pour le Développement, Niakhar, Senegal.
authors.forename: Bou
authors.initials: B
authors.lastname: Diarra
authors.affiliation: Centre pour le Développement des Vaccins, Ministère de la Santé, Bamako, Mali.
authors.forename: Fadima Cheick
authors.initials: FC
authors.lastname: Haidara
authors.affiliation: Navrongo Health Research Centre, Ghana Health Service, Navrongo, Ghana.
authors.forename: Patrick Odum
authors.initials: PO
authors.lastname: Ansah
authors.affiliation: Vaccines and Immunity Theme, Medical Research Council Unit, Basse, The Gambia.
authors.forename: Beate
authors.initials: B
authors.lastname: Kampmann
authors.affiliation: Meningitis Vaccine Project, PATH, Ferney-Voltaire, France.
authors.forename: Enricke
authors.initials: E
authors.lastname: Bouma
authors.affiliation: Meningitis Vaccine Project, PATH, Ferney-Voltaire, France Meningitis Vaccine Project, Department of Immunization, Vaccines and Biologicals, World Health Organization, Geneva, Switzerland.
authors.forename: Marie-Pierre
authors.initials: MP
authors.lastname: Preziosi
authors.affiliation: Meningitis Vaccine Project, PATH, Ferney-Voltaire, France.
authors.forename: Godwin C
authors.initials: GC
authors.lastname: Enwere
mesh_terms: D017954:Africa South of the Sahara / Q000453:epidemiology; D002986:Clinical Trials as Topic; D018864:Cultural Diversity; D018562:Disease Transmission, Infectious / Q000517:prevention & control*; D006801:Humans; D008585:Meningitis, Meningococcal / Q000453:epidemiology / Q000517:prevention & control*; D022401:Meningococcal Vaccines / Q000008:administration & dosage / Q000009:adverse effects* / Q000276:immunology*; D010342:Patient Acceptance of Health Care
chemical_list: C573970:MenAfriVac; D022401:Meningococcal Vaccines
keywords: Africa; MenAfriVac; community perspective; vaccine trial